Hot Investor Mandate: Eastern USA-Based VC Firm Invests Up to $15M in Early-Stage Companies Working on Cancer Therapeutics & Regenerative Medicine

11 Oct

A venture capital firm based in Eastern USA makes initial investments from $5-$15M with $35M over the lifetime of the company. The firm invests globally and has particular experience with partners located in the United States, Israel, and the United Kingdom.

The firm seeks early-stage nanotechnology and stem cell research, particularly in cancer, therapeutic and regenerative medicine. The firm is primarily interested in clinical stage Ph I/II technology. The firm focuses their expertise in regenerative and therapeutic medicine, with a focus on stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. Specific to oncology, the firm is interested in novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

The firm requires management teams with experience in the field. The firm seeks board representation post-investment and remains actively supportive with portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: